Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Качество и продолжительность жизни как основные приоритеты пациентов с распространенным раком молочной железы, получающих лекарственную терапию. Результаты социологического исследования
Качество и продолжительность жизни как основные приоритеты пациентов с распространенным раком молочной железы, получающих лекарственную терапию. Результаты социологического исследования
Коломейцева А.А., Бокова С.Е. Качество и продолжительность жизни как основные приоритеты пациентов с распространенным раком молочной железы, получающих лекарственную терапию. Результаты социологического исследования. Современная Онкология. 2022;24(1):115–118.
DOI: 10.26442/18151434.2022.1.201440
DOI: 10.26442/18151434.2022.1.201440
DOI: 10.26442/18151434.2022.1.201440
________________________________________________
DOI: 10.26442/18151434.2022.1.201440
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Актуальность. Рак молочной железы (РМЖ) занимает лидирующие позиции в структуре онкологической заболеваемости у женщин. Метастатический РМЖ остается неизлечимым заболеванием, основными целями лечения которого являются увеличение продолжительности жизни и улучшение ее качества.
Цель. Оценить приоритеты пациентов с диагнозом «Рак молочной железы» в рамках социологического исследования.
Материалы и методы. Впервые представлены основные результаты социологического исследования пациенток с диагнозом «Рак молочной железы», проведенного Межрегиональным общественным движением «Движение против рака». Данный анализ отражает потребности пациентов, получающих терапию по поводу РМЖ в различных регионах РФ. Всего было опрошено 675 человек, к анализу допущено 662 анкеты.
Результаты. В рейтинге желаний пациентов в отношении результатов лечения независимо от региона и длительности течения болезни лидирующие позиции заняли улучшение качества жизни (46,2%) и увеличение продолжительности жизни (46,4%). В рейтинге предпочтений относительно получаемой терапии 1-е место заняла ценность: «Важно сохранить хорошее самочувствие, работоспособность и возможность жить полноценно» (39,1%).
Заключение. Основными приоритетами пациентов с диагнозом «Рак молочной железы», получающих лекарственную терапию в рамках проведенного социологического исследования, являются увеличение продолжительности жизни и сохранение ее качества на высоком уровне.
Ключевые слова: рак молочной железы, ингибиторы CDK 4/6, качество жизни, продолжительность жизни
Aim. To assess the priorities of patients with breast cancer in the framework of a sociological study.
Materials and methods. For the first time, the main results of a sociological study of patients diagnosed with breast cancer, conducted by the Interregional Public Movement "Movement Against Cancer" in October–November 2021. This analysis reflects the needs of patients with breast cancer in various regions of the Russian Federation. A total of 675 people were interviewed, 662 questionnaires were allowed for analysis.
Results. In the rating of patients' desires regarding the results of treatment, regardless of the region and the duration of the course of the disease, the leading positions were taken by "improved quality of life" (46.2%) and "increased life expectancy" (46.4%). In the rating of preferences regarding the therapy received, the first place was taken by the value “It is important to maintain good health, working capacity and the ability to live a full life” (39.1%).
Conclusion. The priority for all patients diagnosed with breast cancer is an effective and safe treatment that will ensure a good health and performance and safe a high quality of life for a long time.
Keywords: breast cancer, CDK 4/6 inhibitors, quality of life, overall survival
Цель. Оценить приоритеты пациентов с диагнозом «Рак молочной железы» в рамках социологического исследования.
Материалы и методы. Впервые представлены основные результаты социологического исследования пациенток с диагнозом «Рак молочной железы», проведенного Межрегиональным общественным движением «Движение против рака». Данный анализ отражает потребности пациентов, получающих терапию по поводу РМЖ в различных регионах РФ. Всего было опрошено 675 человек, к анализу допущено 662 анкеты.
Результаты. В рейтинге желаний пациентов в отношении результатов лечения независимо от региона и длительности течения болезни лидирующие позиции заняли улучшение качества жизни (46,2%) и увеличение продолжительности жизни (46,4%). В рейтинге предпочтений относительно получаемой терапии 1-е место заняла ценность: «Важно сохранить хорошее самочувствие, работоспособность и возможность жить полноценно» (39,1%).
Заключение. Основными приоритетами пациентов с диагнозом «Рак молочной железы», получающих лекарственную терапию в рамках проведенного социологического исследования, являются увеличение продолжительности жизни и сохранение ее качества на высоком уровне.
Ключевые слова: рак молочной железы, ингибиторы CDK 4/6, качество жизни, продолжительность жизни
________________________________________________
Aim. To assess the priorities of patients with breast cancer in the framework of a sociological study.
Materials and methods. For the first time, the main results of a sociological study of patients diagnosed with breast cancer, conducted by the Interregional Public Movement "Movement Against Cancer" in October–November 2021. This analysis reflects the needs of patients with breast cancer in various regions of the Russian Federation. A total of 675 people were interviewed, 662 questionnaires were allowed for analysis.
Results. In the rating of patients' desires regarding the results of treatment, regardless of the region and the duration of the course of the disease, the leading positions were taken by "improved quality of life" (46.2%) and "increased life expectancy" (46.4%). In the rating of preferences regarding the therapy received, the first place was taken by the value “It is important to maintain good health, working capacity and the ability to live a full life” (39.1%).
Conclusion. The priority for all patients diagnosed with breast cancer is an effective and safe treatment that will ensure a good health and performance and safe a high quality of life for a long time.
Keywords: breast cancer, CDK 4/6 inhibitors, quality of life, overall survival
Полный текст
Список литературы
1. Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М. 2020 [Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2019 godu. Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow. 2020 (in Russian)].
2. Son BH, Ahn SH, Kwak BS, et al. The Recurrence Rate, Risk Factors and Recurrence Patterns after Surgery in 3700 Patients with Operable Breast Cancer. J Breast Cancer. 2006;9(2):134. DOI:10.4048/jbc.2006.9.2.134
3. Pan H, Gray R, Braybrooke J, et al. EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-46. DOI:10.1056/NEJMoa1701830
4. Yersal O, Barutсa S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-24.
5. Bonotto M, Gerratana L, Poletto E, et al. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. Oncologist. 2014;19(6):608‑15.
6. Cuyún G, Mohanty M, Stenger K, et al. Prognostic Factors in Hormone Receptor-
Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER-2) Advanced Breast Cancer: A Systematic Literature Review. Cancer Manag Res. 2021;13:6537-66.
7. Артамонова Е.В. Лекарственное лечение метастатического рака молочной железы. Опухоли женской репродуктивной системы. 2011;4:46-54 [Artamonova EV. Lekarstvennoe lechenie metastaticheskogo raka molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2011;4:46-54 (in Russian)].
8. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33:1890-903. DOI:10.1038/ onc.2013.137
9. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382:514-24.
10. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015-24.
11. Hortobagyi G, Stemmer SM, Burris HA, et al. Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer treated with endocrine therapy ± ribociclib. Ann Oncol. 2021;32(5):S1283-346.
12. Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307-16.
13. Tripathy D, Im S-A, Colleoni M, et al. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Res. 2021;81(Suppl. 4):PD2-04. DOI:10.1158/1538-7445.SABCS20-PD2-04
14. Sledge GW, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116-24. DOI:10.1001/jamaoncol.2019.4782
15. Turner N, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379:1926-36.
16. Aaronson N, Cull A, Kaasa S, Sprangers M. The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int О Ment Health. 1994;23:75-96.
17. Fasching PA, Harbeck N, Jerusalem G, et al. 233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials. Ann Oncol. 2021;32(6):S460.
DOI:10.1016/j.annonc.2021.08.516
18. Harbeck N, Franke F, Villanueva-Vazquez R, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol. 2020;12:1758835920943065. DOI:10.1177/1758835920943065
19. Социологическое исследование субъект-объектных отношений больных раком молочной железы. Режим доступа: http://www.rakpobedim.ru/press/news/socilogicheskoe-issledovanie-subekt-obektnykh-otnosheiu Ссылка активна на 11.03.2022 [Sotsiologicheskoe issledovanie sub"ekt-ob"ektnykh otnoshenii bol'nykh rakom molochnoi zhelezy. Available at: http://www.rakpobedim.ru/press/news/socilogicheskoe-issledovanie-subekt-obektnykh-otnosheiu Accessed: 11.03.2022 (in Russian)].
2. Son BH, Ahn SH, Kwak BS, et al. The Recurrence Rate, Risk Factors and Recurrence Patterns after Surgery in 3700 Patients with Operable Breast Cancer. J Breast Cancer. 2006;9(2):134. DOI:10.4048/jbc.2006.9.2.134
3. Pan H, Gray R, Braybrooke J, et al. EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-46. DOI:10.1056/NEJMoa1701830
4. Yersal O, Barutсa S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-24.
5. Bonotto M, Gerratana L, Poletto E, et al. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. Oncologist. 2014;19(6):608‑15.
6. Cuyún G, Mohanty M, Stenger K, et al. Prognostic Factors in Hormone Receptor-
Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER-2) Advanced Breast Cancer: A Systematic Literature Review. Cancer Manag Res. 2021;13:6537-66.
7. Artamonova EV. Lekarstvennoe lechenie metastaticheskogo raka molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2011;4:46-54 (in Russian).
8. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33:1890-903. DOI:10.1038/ onc.2013.137
9. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382:514-24.
10. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015-24.
11. Hortobagyi G, Stemmer SM, Burris HA, et al. Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer treated with endocrine therapy ± ribociclib. Ann Oncol. 2021;32(5):S1283-346.
12. Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307-16.
13. Tripathy D, Im S-A, Colleoni M, et al. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Res. 2021;81(Suppl. 4):PD2-04. DOI:10.1158/1538-7445.SABCS20-PD2-04
14. Sledge GW, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116-24. DOI:10.1001/jamaoncol.2019.4782
15. Turner N, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379:1926-36.
16. Aaronson N, Cull A, Kaasa S, Sprangers M. The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int О Ment Health. 1994;23:75-96.
17. Fasching PA, Harbeck N, Jerusalem G, et al. 233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials. Ann Oncol. 2021;32(6):S460.
DOI:10.1016/j.annonc.2021.08.516
18. Harbeck N, Franke F, Villanueva-Vazquez R, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol. 2020;12:1758835920943065. DOI:10.1177/1758835920943065
19. Sotsiologicheskoe issledovanie sub"ekt-ob"ektnykh otnoshenii bol'nykh rakom molochnoi zhelezy. Available at: http://www.rakpobedim.ru/press/news/socilogicheskoe-issledovanie-subekt-obektnykh-otnosheiu Accessed: 11.03.2022 (in Russian).
2. Son BH, Ahn SH, Kwak BS, et al. The Recurrence Rate, Risk Factors and Recurrence Patterns after Surgery in 3700 Patients with Operable Breast Cancer. J Breast Cancer. 2006;9(2):134. DOI:10.4048/jbc.2006.9.2.134
3. Pan H, Gray R, Braybrooke J, et al. EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-46. DOI:10.1056/NEJMoa1701830
4. Yersal O, Barutсa S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-24.
5. Bonotto M, Gerratana L, Poletto E, et al. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. Oncologist. 2014;19(6):608‑15.
6. Cuyún G, Mohanty M, Stenger K, et al. Prognostic Factors in Hormone Receptor-
Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER-2) Advanced Breast Cancer: A Systematic Literature Review. Cancer Manag Res. 2021;13:6537-66.
7. Артамонова Е.В. Лекарственное лечение метастатического рака молочной железы. Опухоли женской репродуктивной системы. 2011;4:46-54 [Artamonova EV. Lekarstvennoe lechenie metastaticheskogo raka molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2011;4:46-54 (in Russian)].
8. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33:1890-903. DOI:10.1038/ onc.2013.137
9. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382:514-24.
10. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015-24.
11. Hortobagyi G, Stemmer SM, Burris HA, et al. Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer treated with endocrine therapy ± ribociclib. Ann Oncol. 2021;32(5):S1283-346.
12. Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307-16.
13. Tripathy D, Im S-A, Colleoni M, et al. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Res. 2021;81(Suppl. 4):PD2-04. DOI:10.1158/1538-7445.SABCS20-PD2-04
14. Sledge GW, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116-24. DOI:10.1001/jamaoncol.2019.4782
15. Turner N, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379:1926-36.
16. Aaronson N, Cull A, Kaasa S, Sprangers M. The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int О Ment Health. 1994;23:75-96.
17. Fasching PA, Harbeck N, Jerusalem G, et al. 233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials. Ann Oncol. 2021;32(6):S460.
DOI:10.1016/j.annonc.2021.08.516
18. Harbeck N, Franke F, Villanueva-Vazquez R, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol. 2020;12:1758835920943065. DOI:10.1177/1758835920943065
19. Социологическое исследование субъект-объектных отношений больных раком молочной железы. Режим доступа: http://www.rakpobedim.ru/press/news/socilogicheskoe-issledovanie-subekt-obektnykh-otnosheiu Ссылка активна на 11.03.2022 [Sotsiologicheskoe issledovanie sub"ekt-ob"ektnykh otnoshenii bol'nykh rakom molochnoi zhelezy. Available at: http://www.rakpobedim.ru/press/news/socilogicheskoe-issledovanie-subekt-obektnykh-otnosheiu Accessed: 11.03.2022 (in Russian)].
________________________________________________
2. Son BH, Ahn SH, Kwak BS, et al. The Recurrence Rate, Risk Factors and Recurrence Patterns after Surgery in 3700 Patients with Operable Breast Cancer. J Breast Cancer. 2006;9(2):134. DOI:10.4048/jbc.2006.9.2.134
3. Pan H, Gray R, Braybrooke J, et al. EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-46. DOI:10.1056/NEJMoa1701830
4. Yersal O, Barutсa S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-24.
5. Bonotto M, Gerratana L, Poletto E, et al. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. Oncologist. 2014;19(6):608‑15.
6. Cuyún G, Mohanty M, Stenger K, et al. Prognostic Factors in Hormone Receptor-
Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER-2) Advanced Breast Cancer: A Systematic Literature Review. Cancer Manag Res. 2021;13:6537-66.
7. Artamonova EV. Lekarstvennoe lechenie metastaticheskogo raka molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2011;4:46-54 (in Russian).
8. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33:1890-903. DOI:10.1038/ onc.2013.137
9. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382:514-24.
10. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015-24.
11. Hortobagyi G, Stemmer SM, Burris HA, et al. Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer treated with endocrine therapy ± ribociclib. Ann Oncol. 2021;32(5):S1283-346.
12. Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307-16.
13. Tripathy D, Im S-A, Colleoni M, et al. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Res. 2021;81(Suppl. 4):PD2-04. DOI:10.1158/1538-7445.SABCS20-PD2-04
14. Sledge GW, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116-24. DOI:10.1001/jamaoncol.2019.4782
15. Turner N, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379:1926-36.
16. Aaronson N, Cull A, Kaasa S, Sprangers M. The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int О Ment Health. 1994;23:75-96.
17. Fasching PA, Harbeck N, Jerusalem G, et al. 233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials. Ann Oncol. 2021;32(6):S460.
DOI:10.1016/j.annonc.2021.08.516
18. Harbeck N, Franke F, Villanueva-Vazquez R, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol. 2020;12:1758835920943065. DOI:10.1177/1758835920943065
19. Sotsiologicheskoe issledovanie sub"ekt-ob"ektnykh otnoshenii bol'nykh rakom molochnoi zhelezy. Available at: http://www.rakpobedim.ru/press/news/socilogicheskoe-issledovanie-subekt-obektnykh-otnosheiu Accessed: 11.03.2022 (in Russian).
Авторы
А.А. Коломейцева*1, С.Е. Бокова2
1 Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Москва, Россия;
2 МОД «Движение против рака», Москва, Россия
*almed2002@mail.ru
1 Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre, Moscow, Russia;
2 Interregional Social Movement "Movement against Cancer", Moscow, Russia
*almed2002@mail.ru
1 Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Москва, Россия;
2 МОД «Движение против рака», Москва, Россия
*almed2002@mail.ru
________________________________________________
1 Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre, Moscow, Russia;
2 Interregional Social Movement "Movement against Cancer", Moscow, Russia
*almed2002@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.